Tumor necrosis factor-alpha as a potential therapeutic target in idiopathic inflammatory myopathies

Journal of Neurology

Volumn 258, Issue 6, 2011, Pages 961-970

  Stübgen, Joerg Patrick ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Inflammatory myopathy; TNF antagonists; Tumor necrosis factor alpha

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RITUXIMAB; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

B CELL LYMPHOMA; BIOLOGICAL THERAPY; CORTICOSTEROID THERAPY; DERMATOMYOSITIS; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INCLUSION BODY MYOSITIS; INTERSTITIAL PNEUMONIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MIXED CONNECTIVE TISSUE DISEASE; MYOSITIS; NECROTIZING FASCIITIS; OPPORTUNISTIC INFECTION; POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; STAPHYLOCOCCAL PNEUMONIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE;

ADULT; ANIMALS; ANTI-INFLAMMATORY AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOSITIS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 79959853191     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-011-5907-2     Document Type: Review

References (103)

1. H Lepidi V Frances D Figarella-Branger C Bartoli A Machado-Baeta JF Pellissier 1998 Local expression of cytokines in idiopathic inflammatory myopathies Neuropathol Appl Neurobiol 24 73 79 9549732 10.1046/j.1365-2990.1998. 00092.x 1:CAS:528:DyaK1cXitlCgs7Y%3D (Pubitemid 28105417)
2. D Figarella-Branger M Civate C Bartoli JF Pellissier 2003 Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies Muscle Nerve 28 659 682 14639580 10.1002/mus.10462 1:CAS:528:DC%2BD2cXht1Cjug%3D%3D (Pubitemid 37484828)
3. S Salomonsson IE Lundberg 2006 Cytokines in idiopathic inflammatory myopathies Autoimmunity 39 177 190 16769651 10.1080/08916930600622256 1:CAS:528:DC%2BD28XnsFGltb4%3D (Pubitemid 43879030)
4. A Cope R Ettinger H McDevitt 1997 The role of TNF-α and related cytokines in the development and function of the autoreactive T-cell repertoire Res Immunol 148 307 312 9352594 10.1016/S0923-2494(97)87239-2 1:CAS:528:DyaK2sXnsl2nt7g%3D (Pubitemid 27435914)
5. G Kollias E Douni G Kassiotis D Kontoyiannis 1999 The role of tumor necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease Ann Rheum Dis 58 Suppl 32 39 10.1136/ard.58.2008.i32
6. WH Robinson MC Genovese LW Moreland 2001 Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 44 1977 1983 11592357 10.1002/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6 1:CAS:528:DC%2BD3MXpt12lsbg%3D (Pubitemid 33644038)
7. FW Goetz JV Planas S Mackenzie 2004 Tumor necrosis factors Dev Comp Immunol 28 287 297 10.1016/j.dci.2003.09.008 (Pubitemid 38177449)
8. HT Idriss J Naismith 2000 TNF alpha and the TNF receptor superfamily: structure-function relationship(s) Microsc Res Tech 50 184 195 10891884 10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H 1:CAS:528:DC%2BD3cXmtVeqtbk%3D (Pubitemid 30610095)
9. DJ MacEwan 2002 TNF receptor subtype signaling: differences and cellular consequences Cell Signal 14 477 492 11897488 10.1016/S0898-6568(01)00262-5 1:CAS:528:DC%2BD38XhvVWrsrs%3D (Pubitemid 34230583)
10. MR Slowik LG De Luca W Fiers JS Pober 1993 Tumor necrosis factor activates human endothelial cells through the p55 tumor necrosis receptor but the p75 receptor contributes to activation at low tumor necrosis factor concentration Am J Pathol 143 1724 1730 7504889 1:CAS:528:DyaK2cXitFGjt78%3D (Pubitemid 24058275)
11. F Mackay H Loetscher D Stueber G Gehr W Lesslauer 1993 Tumor necrosis factor alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55 J Exp Med 177 1277 1286 8386742 10.1084/jem.177.5.1277 1:CAS:528:DyaK3sXitFWisb0%3D (Pubitemid 23117119)
12. JA Barbara WB Smith JR Gamble X Van Ostade P Vandenabeele J Tavernier W Fiers MA Vadas AF Lopez 1994 Dissociation of TNF-alpha cytotoxic and proinflammatory activities by p55 receptor- and p75 receptor-selective TNF-alpha mutants EMBO J 13 843 850 7509279 1:CAS:528:DyaK2cXitFCqur4%3D
13. MH Holtmann MF Neurath 2004 Differential TNF-signaling in chronic inflammatory disorders Curr Mol Med 4 439 444 15354874 10.2174/1566524043360636 1:CAS:528:DC%2BD2cXksFGjt7g%3D (Pubitemid 38787012)
14. Y Mukai H Shibata T Nakamura Y Abe T Nomura M Taniai T Ohta S Ikemizu S Nakagawa S Tsunoda H Kamada Y Yamagata Y Tsusumi 2009 Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant J Mol Biol 385 1221 1229 19084540 10.1016/j.jmb.2008.11.053 1:CAS:528: DC%2BD1MXntFemsg%3D%3D
15. C Hofmann K Lorenz SS Braithwaite JR Colca BJ Palazuk GS Hotamisligil BM Spiegelman 1994 Altered gene expression for tumor necrosis factor-alpha and its receptor during drug and dietary modulation of insulin resistance Endocrinology 134 264 270 8275942 10.1210/en.134.1.264 1:CAS:528:DyaK2cXpslSiug%3D%3D (Pubitemid 24021997)
16. M Chabaud F Fossiez JL Taupin P Miossec 1998 Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines J Immunol 161 409 414 9647250 1:CAS:528:DyaK1cXktVynsbs%3D (Pubitemid 28285549)
17. K Nagaraju N Raben G Merritt L Loeffler K Kirk P Plotz 1998 A variety of cytokines and immunologically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli Clin Exp Immunol 113 407 414 9737670 10.1046/j.1365-2249.1998.00664.x 1:CAS:528:DyaK1cXmsVOlsL8%3D (Pubitemid 28410566)
18. Y Seko H Matsuda K Kato Y Hashimoto H Yagita K Okumura Y Yazaki 1993 Expression of intercellular adhesion molecule-1 in murine hearts with acute myocarditis caused by coxsackie virus B3 J Clin Invest 91 1327 1336 8097205 10.1172/JCI116333 1:CAS:528:DyaK3sXisFantL8%3D (Pubitemid 23127329)
19. D Michaelis N Goebels R Hohlfeld 1993 Constitutive and cytokine-induced expression of human leukocyte antigens and cell adhesion molecules by human myotubes Am J Pathol 143 1142 1149 8214008 1:CAS:528:DyaK2cXhs1WhsLc%3D (Pubitemid 24070556)
20. JL De Bleecker AG Engel 1994 Expression of cell adhesion molecules in inflammatory myopathies and Duchenne dystrophy J Neuropathol Exp Neurol 53 369 376 8021710 10.1097/00005072-199407000-00008 (Pubitemid 24216036)
21. B Moser M Wolf A Waltz P Loetscher 2004 Chemokines: multiple levels of leukocyte migration control Trends Immunol 25 75 84 15102366 10.1016/j.it.2003.12.005 1:CAS:528:DC%2BD2cXpsVGhsg%3D%3D (Pubitemid 38167488)
22. ENBREL (etanercept) (2007) Current prescribing information. In: Physicians' desk reference. Thompson, Montvale, pp 584-591
23. HUMIRA (adalimumab) (2007) Current prescribing information. In: Physicians' desk reference. Thompson, Montvale, pp 466-471
24. G Page G Chevrel P Miossec 2004 Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: interaction with chemokines and Th1 cytokine-producing cells Arthritis Rheum 50 199 208 14730617 10.1002/art.11428 1:CAS:528:DC%2BD2cXht1Kru7k%3D (Pubitemid 38084305)
25. P Scheurich B Thoma U Ucer K Pfizenmaier 1987 Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses J Immunol 138 1786 1790 3029221 1:CAS:528:DyaL2sXhslCnsrs%3D (Pubitemid 17040802)
26. AP Cope RS Liblau XD Yang M Congia C Laudanna RD Schreiber L Probert G Kollias HO McDevitt 1997 Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling J Exp Med 185 1573 1584 9151895 10.1084/jem.185.9.1573 1:CAS:528:DyaK2sXjtVOisLo%3D (Pubitemid 27203254)
27. SA Greenberg 2009 Inflammatory myopathies: disease mechanisms Curr Opin Neurol 22 516 523 19680126 10.1097/WCO.0b013e3283311ddf 1:CAS:528: DC%2BD1MXhtFanurvJ
28. VS Limaye P Blimbergs PJ Roberts-Thomson 2009 Idiopathic inflammatory myopathies Intern Med J 39 179 190 19006486 10.1111/j.1445-5994.2008.01822.x 1:CAS:528:DC%2BD1MXmtFejtLc%3D
29. MS Krathen D Fiorentino VP Werth 2008 Dermatomyositis Curr Dir Autoimmun 10 313 332 18460893 10.1159/000131751 1:CAS:528:DC%2BD1MXltFeht70%3D
30. S Khanna AM Reed 2010 Immuno pathogenesis of juvenile dermatomyositis Muscle Nerve 41 581 592 20405498 10.1002/mus.21669 1:CAS:528: DC%2BC3cXms1Cms78%3D
31. AL Mammen 2010 Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis Ann N Y Acad Sci 1184 134 153 20146695 10.1111/j.1749-6632.2009.05119.x 1:CAS:528:DC%2BC3cXivVegtLo%3D
32. AA Amato RJ Barohn 2009 Inclusion body myositis: old and new concepts J Neurol Neurosurg Psychiatry 80 1186 1193 19864656 10.1136/jnnp.2009.173823 1:STN:280:DC%2BD1Mjit1Ohtg%3D%3D
33. SA Greenberg 2010 Theories of the pathogenesis of inclusion body myositis Curr Rheumatol Rep 12 221 228 20425523 10.1007/s11926-010-0102-5 1:CAS:528:DC%2BC3cXht1CjsbrL
34. T Shimizu Y Tomita K Son S Nishinarita S Sawada T Horie 2000 Elevation of serum soluble tumor necrosis factor receptors in patients with polymyositis and dermatomyositis Clin Rheumatol 19 352 359 11055823 10.1007/s100670070027 1:STN:280:DC%2BD3crgsFWnsA%3D%3D
35. S Kuru A Inukai Y Liang M Doyu A Takano G Sobue 2000 Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis Acta Neuropathol 99 585 588 10805105 10.1007/s004010051165 1:CAS:528: DC%2BD3cXhvF2mu7s%3D (Pubitemid 30201324)
36. S Kuru A Inukai T Kato Y Liang S Kimura G Sobue 2003 Expression of tumor necrosis factor-alpha in regenerating muscle fibers in inflammatory and non-inflammatory myopathies Acta Neuropathol (Berl) 105 217 224 1:CAS:528:DC%2BD3sXntV2iug%3D%3D (Pubitemid 36798812)
37. JL De Bleecker VI Meire W Declerq EH Van Aken 1999 Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies Neuromuscul Disord 9 239 246 10399751 10.1016/S0960-8966(98)00126-6 (Pubitemid 29287259)
38. JM Peterson KD Feeback JH Baas FX Pizza 2006 Tumor necrosis factor-alpha promotes the accumulation of neutrophils and macrophages in skeletal muscle J Appl Physiol 101 1394 1399 16840574 10.1152/japplphysiol.01453.2005 1:CAS:528:DC%2BD28Xht1Ois77N
39. J Schmidt K Barthel A Wrede M Salajegheh M Bahr MC Dalakas 2008 Interrelation of inflammation and APP in sIBM: IL-1β induces accumulation of β-amyloid in skeletal muscle Brain 131 1228 1240 18420712 10.1093/brain/awn053
40. S Gallucci C Provenzano P Mazzarelli F Scuderi E Bartoccioni 1998 Myoblasts produce IL-6 in response to inflammatory stimuli Int Immunol 10 267 273 9576614 10.1093/intimm/10.3.267 1:CAS:528:DyaK1cXisVOqsLg%3D (Pubitemid 28132712)
41. SE Chen B Jin YP Li 2007 TNF-alpha regulates myogenesis and muscle regeneration by activating p38 MAPK Am J Physiol Cell Physiol 292 1660 1671 10.1152/ajpcell.00486.2006 (Pubitemid 47080547)
42. RC Langen JL van der Velden AM Schols MC Kelders EF Wouters YM Janssen-Heininger 2004 Tumor necrosis factor-alpha inhibits myogenic differentiation through MyoD protein destabilization FASEB J 18 227 237 14769817 10.1096/fj.03-0251com 1:CAS:528:DC%2BD2cXht1Ghurc%3D (Pubitemid 38186242)
43. SH Lecker V Solomon WE Mitch AL Goldberg 1999 Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states J Nutr 129 Suppl 1 227 237
44. CA Dinarello 1996 Biologic basis for interleukin-1 in disease Blood 87 2095 2147 8630372 1:CAS:528:DyaK28Xhs1CktLc%3D (Pubitemid 26086851)
45. KJ Tracey SF Lowry B Beutler A Cerami JD Albert GT Shires 1986 Cachectin/tumor necrosis factor mediates changes of skeletal muscle plasma membrane potential J Exp Med 164 1368 1373 3760781 10.1084/jem.164.4.1368 1:CAS:528:DyaL28XlvV2itLo%3D (Pubitemid 16031632)
46. MD Lee A Zentella W Vine PH Pekala A Cerami 1987 Effect of endotoxin-induced monokines on glucose metabolism in the muscle cell line L6 Proc Natl Acad Sci USA 84 2590 2594 3472226 10.1073/pnas.84.9.2590 1:CAS:528:DyaL2sXkt1Wks70%3D (Pubitemid 17064698)
47. EA Flores BR Bistrian JJ Pomposelli CA Dinarello GL Blackburn NW Istfan 1989 Infusion of tumor necrosis factor/cachectin promotes muscle catabolism in the rat. A synergistic effect with interleukin 1 J Clin Invest 83 1614 1622 2785120 10.1172/JCI114059 1:CAS:528:DyaL1MXit12rtL4%3D (Pubitemid 19124117)
48. MN Goodman 1991 Tumor necrosis factor induces skeletal muscle protein breakdown in rats Am J Physiol 260 E727 E730 2035628 1:CAS:528: DyaK3MXktVKksLw%3D
49. C Garcia-Martinez N Agell M Llovera FJ Lopez-Soriano JM Argiles 1993 Tumor necrosis factor-alpha increases the ubiquitinization of rat skeletal muscle proteins FEBS Lett 323 211 214 8388807 10.1016/0014-5793(93)81341-V 1:CAS:528:DyaK3sXksVOiu7w%3D (Pubitemid 23153471)
50. MB Reid YP Li 2001 Tumor necrosis factor-alpha and muscle wasting: a cellular perspective Respir Res 2 269 271 11686894 10.1186/rr67 1:CAS:528:DC%2BD3MXosVequ78%3D (Pubitemid 34189649)
51. MB Reid J Lannergren H Westerblad 2002 Respiratory and limb muscle weakness induced by tumor necrosis factor alpha: involvement of muscle myofilaments Am J Respir Crit Care Med 166 479 484 12186824 10.1164/rccm.2202005
52. LM Pachman MR Liotta-Davis DK Hong TR Kinsella EP Mendez JM Kinder EH Chen 2000 TNFalpha-308 allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications Arthritis Rheum 43 2368 2377 11037898 10.1002/1529-0131(200010)43:10<2368::AID-ANR26>3.0.CO;2-8 1:CAS:528:DC%2BD3cXnslWjsLY%3D
53. LM Pachman TO Fedczyna TS Lechman J Lutz 2001 Juvenile dermatomyositis: the association of the TNF alpha-308A allele and disease chronicity Curr Rheumatol Rep 3 379 386 11564368 10.1007/s11926-996-0007-5 1:STN:280: DC%2BD38%2FmtlWnsQ%3D%3D
54. VP Werth JP Callen G Ang KE Sullivan 2002 Associations of tumor necrosis factor alpha and HLA polymorphisms with adult dermatomyositis: implications for a unique pathogenesis J Invest Dermatol 119 617 620 12230503 10.1046/j.1523-1747.2002.01869.x 1:CAS:528:DC%2BD38Xnt1yhu70%3D
55. AB Hassan L Nikitina-Zake CB Sanjeevi IE Lundberg L Padyukov 2004 Association of the proinflammatory haplotype(MICA5.1/TNF2/TNFα2/ DRB1*03) with polymyositis and dermatomyositis Arthritis Rheum 50 1013 1015 15022353 10.1002/art.20208 1:CAS:528:DC%2BD2cXjtVCrsLc%3D (Pubitemid 38326208)
56. AB Hassan M Fathi M Dastmalchi IE Lundberg L Padyukov 2006 Genetically determined imbalance between serum levels of tumour necrosis factor (TNF) and interleukin (IL)-10 is associated with anti-Jo-1 and anti-Ro52 autoantibodies in patients with poly- and dermatomyositis J Autoimmun 27 62 68 16895750 10.1016/j.jaut.2006.06.003 1:CAS:528:DC%2BD28Xosl2qsL8%3D (Pubitemid 44294854)
57. JR Bradley 2008 TNF-mediated inflammatory disease J Pathol 214 149 160 18161752 10.1002/path.2287 1:CAS:528:DC%2BD1cXhvFCktrY%3D (Pubitemid 351160153)
58. REMICADE (infliximab) (2007) Current prescribing information. In: Physicians desk reference. Thompson, Montvale, pp 971-979
59. P Efthimiou 2006 Tumor necrosis factor-alpha in inflammatory myopathies: pathophysiological and therapeutic implications Semin Arthritis Rheum 36 168 172 16970978 10.1016/j.semarthrit.2006.07.003 1:CAS:528:DC%2BD28XhtFOiu7nL (Pubitemid 44691885)
60. ®) in polymyositis and dermatomyositis Arthritis Rheum 43 S193
61. CK Saadeh 2000 Etanercept is effective in the treatment of polymyositis/dermatomyositis which is refractive to conventional therapy including steroid and other disease modifying agents Arthritis Rheum 43 S193
62. R Singh R Cuchacovich W Huang LR Espinoza 2001 Inclusion body myositis unresponsive to etanercept J Clin Rheumatol 7 279 280 17039153 10.1097/00124743-200108000-00024 1:STN:280:DC%2BD28ngs1Citg%3D%3D (Pubitemid 32772094)
63. E Roddy PA Courtney A Morris 2002 Non-Hodgkin's lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab Rheumatology 41 1194 1195 12364644 10.1093/rheumatology/41.10.1194 1:STN:280:DC%2BD38nhtVSntw%3D%3D (Pubitemid 35203552)
64. ®), a recombinant human soluble fusion protein of TNF-α type II receptor and IgG1 Rheumatology 43 524 526 15024139 10.1093/rheumatology/keh062 1:CAS:528:DC%2BD2cXitlyhsLk%3D (Pubitemid 38489376)
65. I Laboiche E Liozon B Weschler P Loustaud-Ratti P Soria E Vidal 2004 Refractory polymyositis responding to infliximab: extended follow-up Rheumatology 43 532 533 10.1093/rheumatology/keh080 (Pubitemid 38489381)
66. I Uhtman J El-Sayad 2004 Refractory polymyositis responding to infliximab Rheumatology 43 1198 1199 10.1093/rheumatology/keh268 (Pubitemid 39232833)
67. C Korkmaz G Temiz F Çetinbas B Büyükkidan 2004 Case report: successful treatment of alveolar hypoventilation due to dermatomyositis with anti-tumour necrosis factor-alpha Rheumatology 43 938 939 10.1093/rheumatology/keh226 (Pubitemid 38996975)
68. A Selva-O'Callaghan X Martînez-Costa R Solans-Laque M Mauri JA Capdevila M Vilardell-Tarrés 2004 Refractory adult dermatomyositis with pneumatosis cystoides intestinalis treated with infliximab Rheumatology 43 1197 1198 10.1093/rheumatology/keh293 (Pubitemid 39232832)
69. I Marie P Heliot F Roussel F Hervé JF Muir H Levesque 2005 Fatal Mycobacterium peregrinum pneumonia in refractory polymyositis treated with infliximab Rheumatology 44 1202 1203 10.1093/rheumatology/keh677 (Pubitemid 41236038)
70. A Anandacoomarasamy G Howe N Manolios 2005 Advanced refractory polymyositis responding to infliximab Rheumatology 44 562 563 15695299 10.1093/rheumatology/keh539 1:STN:280:DC%2BD2M7ks1ylsw%3D%3D (Pubitemid 41511155)
71. S Dold ME Justiniano J Marquez LR Espinoza 2007 Treatment of early and refractory dermatomyositis with infliximab: a report of 2 cases Clin Rheumatol 26 1186 1188 16736125 10.1007/s10067-006-0325-z (Pubitemid 46863976)
72. D Wendling C Prati P Ornetti E Toussirot G Streit 2007 Anti TNF-alpha treatment of a refractory polymyositis Rev Med Interne 28 194 195 17240483 10.1016/j.revmed.2006.12.001 1:STN:280:DC%2BD2s7otl2msA%3D%3D (Pubitemid 46341505)
73. KH Choi WH Yoo 2009 Necrotizing fasciitis in a patient treated with etanercept for dermatomyositis Rheumatol Int 29 463 466 18795294 10.1007/s00296-008-0695-4
74. CL Hill Y Zhang B Sigurgeirsson E Pukkula L Mellemkjaer A Airio SR Evans DT Felson 2001 Frequency of specific cancer types in dermatomyositis and polymyositis: a population based study Lancet 357 96 100 11197446 10.1016/S0140-6736(00)03540-6 1:STN:280:DC%2BD3M7nslWltA%3D%3D (Pubitemid 32094911)
75. I Marie E Hachulla P Chérin MF Hellot S Herson H Levesque PY Hatron 2005 Opportunistic infections in polymyositis and dermatomyositis Arthritis Rheum 53 155 165 15818648 10.1002/art.21083 (Pubitemid 40530154)
76. P Efthimiou S Schwartzman LJ Kagen 2006 Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of 8 patients Ann Rheum Dis 65 1233 1236 16476710 10.1136/ard.2005.048744 1:CAS:528:DC%2BD28XpvVensLs%3D (Pubitemid 44277404)
77. F Iannone C Scioscia PC Falappone M Covelli G Lapadula 2006 Use of etanercept in the treatment of dermatomyositis: a case series J Rheumatol 33 1802 1804 16960940 1:CAS:528:DC%2BD28XhtVGisr3P (Pubitemid 44373214)
78. P Riley LJ McCann SM Maillard P Woo KJ Murray CA Pilkington 2008 Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis Rheumatology 47 877 880 18403404 10.1093/rheumatology/ken074 1:CAS:528:DC%2BD1cXmtlentrg%3D (Pubitemid 351796377)
79. JP Vandenbroucke 2001 In defense of case reports and case series Ann Intern Med 134 330 334 11182844 1:STN:280:DC%2BD3M7ktl2rsQ%3D%3D (Pubitemid 32163956)
80. M Noordzij FW Dekker C Zoccali KJ Jager 2009 Study design in clinical research Nephron Clin Pract 113 c218 c221 19690439 10.1159/000235610
81. Jenicek M (1999) Clinical case reporting in evidence-based medicine. Butterworths, Oxford, p 1999
82. RJ Barohn L Herbelin JT Kissel W King AL McVey DS Saperstein JR Mendell 2006 Pilot trial of etanercept in the treatment of inclusion-body myositis Neurology 66 Suppl 1 S123 S124 16432140 1:CAS:528:DC%2BD28Xht1Kquw%3D%3D
83. GJ Hengstman JL de Bleecker E Feist J Vissing CP Denton MN Manoussakis H Slott Jensen BG van Engelen FH van den Hoogen 2008 Open-label trial of anti-TNF-α in dermatomyositis and polymyositis treated concomitantly with methotrexate Eur Neurol 59 159 163 18230873 10.1159/000114036 1:CAS:528:DC%2BD1cXit1yntb0%3D (Pubitemid 351301260)
84. GJ Hengstman FH van den Hoogen P Barrera MG Netea A Pieterse LB van de Putte BG van Engelen 2003 Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations Eur Neurol 50 10 15 12824706 10.1159/000070852 1:CAS:528:DC%2BD3sXkvVegsr0%3D (Pubitemid 36736963)
85. GJ Hengstman FH van den Hoogen BG van Engelen 2004 Treatment of dermatomyositis and polymyositis with anti-tumor-necrosis factor-α: long-term follow-up Eur Neurol 52 61 63 15240986 10.1159/000079547 1:CAS:528:DC%2BD2cXmsV2itro%3D (Pubitemid 39077819)
86. M Dastmalchi C Grundtman H Alexanderson CP Mavragani H Einarsdottir SB Helmers K Elvin MK Crow I Nennesmo IE Lundberg 2008 A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies Ann Rheum Dis 67 1670 1677 18272672 10.1136/ard.2007. 077974 1:CAS:528:DC%2BD1MXjs1OitA%3D%3D
87. M Ramos-Casals P Brito-Zeron S Muñoz N Soria D Galiana L Bertolaccini MJ Cuadrado MA Khamashta 2007 Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases Medicine (Baltimore) 86 242 251 10.1097/MD.0b013e3181441a68 (Pubitemid 47067483)
88. M Ramos-Casals P Brito-Zeron MJ Soto MJ Cuadrado MA Khamashta 2008 Autoimmune diseases induced by TNF-targeted therapies Best Pract Res Clin Rheumatol 22 847 861 19028367 10.1016/j.berh.2008.09.008 1:CAS:528: DC%2BD1cXhsVWmt7rM
89. J Borrås-Biasco A Navarro-Ruiz C Borrås E Casterå 2009 Adverse cutaneous reactions induced by TNF-alpha antagonist therapy South Med J 102 1133 1140 10.1097/SMJ.0b013e3181bb554c
90. DA Wetter MD Davis 2009 Lupus-like syndrome attributable to anti-tumor necrosis factor therapy in 14 patients during an 8-year period at Mayo Clinic Mayo Clin Proc 84 979 984 19880688 10.4065/84.11.979 1:CAS:528: DC%2BD1MXhsVGms7vN
91. M Ramos-Casals Roberto-Perez-Alvarez C Diaz-Lagares MJ Cuadrado MA Khamashta BIOGEAS Study Group 2010 Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 9 188 193 19854301 10.1016/j.autrev.2009.10.003 1:CAS:528:DC%2BC3cXmtlGnsbc%3D
92. N Mohan ET Edwards TR Cupps PJ Oliviero G Sandberg H Crayton JR Richert JN Siegel 2001 Demyelination occurring during anti-tumor necrosis factor α therapy for inflammatory arthritis Arthritis Rheum 44 2862 2869 11762947 10.1002/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W 1:CAS:528:DC%2BD38XislCltA%3D%3D (Pubitemid 34016206)
93. AG Tristano 2010 Neurological adverse events associated with anti-tumor necrosis factor alpha treatment J Neurol 257 1421 1431 20495815 10.1007/s00415-010-5591-7
94. JP Stübgen 2008 Tumor necrosis factor-α antagonists and neuropathy Muscle Nerve 37 281 292 18041052 10.1002/mus.20924 (Pubitemid 351304787)
95. J Musial A Undas M Celinska-Lowenhoff 2003 Polymyositis associated with infliximab treatment for rheumatoid arthritis Rheumatology (Oxford) 42 1566 1568 10.1093/rheumatology/keg388 1:STN:280:DC%2BD3srntFyhug%3D%3D (Pubitemid 37508935)
96. Y Urata Y Wakai K Kowatari T Nitobe Y Mizushima 2006 Polymyositis associated with infliximab treatment for rheumatoid arthritis Mod Rheumatol 16 410 411 17165006 10.1007/s10165-006-0523-1 (Pubitemid 44921592)
97. HA Hall B Zimmermann 2006 Evolution of dermatomyositis during therapy with a tumor necrosis factor α inhibitor Arthritis Rheum 15 982 984 10.1002/art.22358 (Pubitemid 44917476)
98. E Liozon V Outtara V Loustaud-Ratti E Vidal 2007 Severe polymyositis and flare in autoimmunity following treatment with adalimumab in a patient with overlapping features of polyarthritis and scleroderma Scand J Rheumatol 36 484 486 18092275 10.1080/03009740701281293 1:STN:280:DC%2BD2sjltlKruw%3D%3D (Pubitemid 350293532)
99. S Vordenbaumen E Neuen-Jacob J Richter M Schneider 2010 Inclusion body myositis in a patient with long standing rheumatoid arthritis treated with anti-TNFα and rituximab Clin Rheumatol 29 555 558 20108015 10.1007/s10067-009-1367-9
100. JF Colombel EV Loftus Jr WJ Tremaine LJ Egan WS Harmsen CD Schleck AR Zinsmeister WJ Sandborn 2004 The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients Gastroenterology 126 19 31 14699483 10.1053/j.gastro.2003.10.047 1:CAS:528:DC%2BD2cXhtFGnt7c%3D (Pubitemid 38040720)
101. FW Miller EV Hess DJ Clauw PA Hertzman T Pincus RM Silver MD Mayes J Varga TA Medsger Jr LA Love 2000 Approaches for identifying and defining environmentally associated rheumatic disorders Arthritis Rheum 43 243 249 10693862 10.1002/1529-0131(200002)43:2<243::AID-ANR2>3.0.CO;2-K 1:STN:280:DC%2BD3c7lsFGhuw%3D%3D (Pubitemid 30395731)
102. DA Pitkeathly EN Coomes 1966 Polymyositis in rheumatoid arthritis Ann Rheum Dis 25 127 132 5931007 1:STN:280:DyaF287isV2ltQ%3D%3D
103. IN Targoff 2002 Idiopathic inflammatory myopathy: autoantibody update Curr Rheum Rep 4 434 441 10.1007/s11926-002-0089-7